AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aytu BioPharma, Inc. (AYTU) on June 12, 2023, covering events occurring on June 8, 2023. The filing details the entry into a material definitive agreement for a capital raise and the subsequent appointment of a new director to the Board.
Key Financial Metrics and Transaction Details
The Company entered into a securities purchase agreement for a best-efforts offering expected to generate approximately $4 million in gross proceeds before deducting placement agent fees and offering expenses. The offering structure includes:
- Common Stock: 1,743,695 shares sold at $1.84 per share.
- Pre-Funded Warrants: 430,217 warrants sold at $1.8399 per warrant, exercisable at $0.0001 per share.
- Common Warrants: 2,173,912 Tranche A warrants and 2,173,912 Tranche B warrants accompanying the shares and pre-funded warrants.
- Warrant Exercise Price: $1.59 per share (or $1.5899 for Exchange Warrants).
- Placement Agent Fee: 7.0% of gross proceeds payable to Maxim Group LLC.
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period, as this is a transactional report rather than a periodic financial statement.
Material Changes and Governance
Upon the closing of the offering, the size of the Board of Directors will increase from four to five members. Abhinav Jain, representing investor Nantahala Capital Management, LLC, will be appointed to the Board and to the Audit, Compensation, and Nominating and Governance Committees. Nantahala also retains the right to nominate an additional Board member.
Outlook, Risks, and Contingencies
The offering is expected to close on June 13, 2023, subject to customary closing conditions. The Tranche B Warrants contain a performance-based expiration clause, expiring 30 days after the Company achieves a consolidated trailing twelve-month adjusted EBITDA of $12 million. The filing includes standard forward-looking statement disclaimers, noting risks that the offering may not close as expected or at all.
Key Facts for Investor Verification
- Verify the actual closing date and final gross proceeds of the offering.
- Confirm the dilution impact of the 1,743,695 new shares and the potential exercise of 4,347,824 warrants.
- Monitor the Company's progress toward the $12 million adjusted EBITDA target required to prevent the expiration of Tranche B Warrants.
- Review the full text of the Securities Purchase Agreement and Placement Agency Agreement (Exhibits 10.1 and 10.2) for specific covenants and restrictions.